Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Tilpasning og evaluering af et program for ophør af tobaksbrug for mennesker, der lever med hiv i Uganda og Zambia (Quit4Life)

9. november 2026 opdateret af: University of Southern California

Quit4Life+: Tilpasning og evaluering af et telefonbaseret tobaksophørsprogram for mennesker, der lever med hiv i Uganda og Zambia (Quit4Life+)

This proposal tests the efficacy of a phone-based tobacco cessation intervention for people living with HIV (PLWH) in comparison to the standard of care (brief advice to quit) and nicotine replacement therapy (nicotine patches) in Uganda and Zambia. This study will provide insight into the efficacy, feasibility, applicability, and affordability of delivering tobacco cessation interventions through health care professionals at HIV treatment centers in two countries with different tobacco use patterns, policy environments, and health care resources. The previously tested SMS-platform to be used in this study is uniquely positioned to be scaled in low- and middle-income countries worldwide, in which case rigorous research showing even modest success in reducing the prevalence of tobacco consumption among PLWH could confer substantial health and economic benefits.

Studieoversigt

Detaljeret beskrivelse

While there is substantial evidence supporting interventions to help tobacco users in the general population quit, little is available relevant to the challenges facing HIV+ tobacco users, especially those living in low-income African countries. This study approaches this gap with the first randomized control trial (RCT) to test the efficacy of a tailored short message service (SMS) based tobacco use cessation intervention on prolonged tobacco use abstinence at 6 months post program initiation in comparison to the standard of care (brief advice to quit) and nicotine replacement therapy (nicotine patches) among PLWH in Uganda and Zambia. This study will provide insight into the efficacy, feasibility, applicability, and affordability of delivering tobacco cessation interventions through health care professionals at HIV treatment centers in two countries with different tobacco use patterns, policy environments, and health care resources and provide needed information to providers and policymakers looking for cost-effective tobacco cessation interventions.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

800

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Kampala, Uganda
        • Rekruttering
        • Makerere University
        • Kontakt:
        • Underforsker:
          • Anthony Mbonye, PhD
        • Underforsker:
          • Eizeus Rutebemberwa, MD, PhD
        • Underforsker:
          • David Guwatudde, Bstat,MCs, PhD
        • Underforsker:
          • Lynn Atuyambe, PhD
        • Underforsker:
          • Fred Wabwire Mangen, MBChB, MPH, PhD
      • Lusaka, Zambia
        • Rekruttering
        • University of Zambia
        • Kontakt:
          • Fastone Goma, BSc, MB ChB, Mac, PhD
          • Telefonnummer: 260977772301
          • E-mail: gomafm@yahoo.co.uk
        • Underforsker:
          • Cosmas Zyambo, BSc MB ChB MPhi PhD
        • Underforsker:
          • Richard Zulu, BA MA MPhil

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

-

Exclusion Criteria:

  • Females who are pregnant, planning to get pregnant, or breastfeeding
  • <18 years (underage of consent)
  • Visitor, not receiving continuous care at study site
  • Not a current daily tobacco user
  • Any physical, cognitive, or psychological disabilities that would prevent them from participating in the study
  • Illiterate in English and/or local languages
  • Does not consent

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Ingen indgriben: Standard of Care

This is the baseline group receiving advice to quit.

Aktiv komparator: Nicotine Replacement

This group will receive the standard of care and be prescribed nicotine replacement therapy

Will be receiving nicotine therapy

Andre navne:
  • NicoDerm
Aktiv komparator: Text Messaging

This group will receive the standard of care and receive text message support

Will be enrolled in an texting app

Andre navne:
  • Tekst2Afslut
Aktiv komparator: Nicotine replacement and text messaging

This group will receive the standard of care, be prescribed nicotine replacement therapy, and receive text message support

Will be receiving nicotine therapy

Andre navne:
  • NicoDerm

Will be enrolled in an texting app

Andre navne:
  • Tekst2Afslut

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Prolonged tobacco abstinence
Tidsramme: 6 months post enrollment

The primary outcome for this efficacy trial is the proportion of study participants that have prolonged abstinence (i.e., no tobacco use from the target quit date through follow-up) at 3 and 6 months post enrollment measured by self-report and biochemically-verified as recommended by the Society for Research on Nicotine and Tobacco, the biomarker being assessed is urinary cotinine (<12 ng/mL) at 6 months post enrollment

6 months post enrollment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Point Prevalence
Tidsramme: 4 weeks, 8 weeks, and 3 months post enrollment

7 consecutive days of no tobacco use, biochemically-verified at 4 weeks, 8 weeks, and 3 months post enrollment, the biomarker being assessed is urinary cotinine (<12 ng/mL) at 6 months post enrollment, the measurement tool is urine cotinine dip sticks

4 weeks, 8 weeks, and 3 months post enrollment

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Quit attempts
Tidsramme: 4 weeks, 8 weeks, and 3 months post enrollment

Self-reported quit attempts and changes in tobacco use, monitoring survey, health assessment form

4 weeks, 8 weeks, and 3 months post enrollment
Nicotine patch adherence
Tidsramme: 4 weeks, 8 weeks, and 3 months post enrollment

Self-reported adherence to nicotine patch treatment, monitoring survey, health assessment form

4 weeks, 8 weeks, and 3 months post enrollment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

13. september 2023

Primær færdiggørelse (Anslået)

31. december 2027

Studieafslutning (Anslået)

31. december 2028

Datoer for studieregistrering

Først indsendt

18. juli 2022

Først indsendt, der opfyldte QC-kriterier

1. august 2022

Først opslået (Faktiske)

4. august 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

13. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Our dissemination strategy will target tobacco and HIV stakeholders including Ministry of Health and other government officials, health care organizations, health facility managers, HIV health care providers, tobacco control professionals, non-governmental organizations engaged in HIV and tobacco control, and PLWH. Our investigators will publish study results through peer-reviewed journals and scientific conferences; generate fact sheets and policy briefs; and disseminate our results through websites, social media, television and radio. We will share the study results in the participating Districts and the Cancer Treatments Centers of America will host a workshop in the final year with regional stakeholders to share the study results and promote tobacco use cessation programming for PLWH throughout Sub-saharan Africa. World Health Organization will assist in disseminating the study findings to other low/middle income countries.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner